Home  |  Site Map  |  Contact Us  |  
Search

 

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or relapsing forms of Multiple Sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort recently granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals, Inc. for all indications. XenoPort's pipeline of product candidates also includes a potential treatment for patients with Parkinson's disease.

For more information, please click here


For more information, please click here

Wed, 10 Sep 2014
XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston

Tue, 09 Sep 2014
XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder

 

2014 Morgan Stanley Healthcare Conference
September 9, 2014 at 4:40 pm ET

Q2 2014 XenoPort, Inc. Earnings Conference Call
Aug 6, 2014 at 5:00 PM ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinsonís disease and relapsing-remitting multiple sclerosis.

Explore the XenoPort Pipeline >